Get the Stockscreener App
10.90
17.11%
-2.25
After Hours:
10.90
Uniqure N V Stock (QURE) Latest News
Don't Ignore The Insider Selling In uniQure - Simply Wall St
uniQure Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Insider Selling: uniQure (NASDAQ:QURE) CEO Sells 26,727 Shares of Stock - MarketBeat
uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta Sells 6,717 Shares - MarketBeat
uniQure (NASDAQ:QURE) CFO Christian Klemt Sells 14,341 Shares - MarketBeat
uniQure (NASDAQ:QURE) CFO Christian Klemt Sells 2,916 Shares - MarketBeat
uniQure (NASDAQ:QURE) Releases Quarterly Earnings Results, Misses Expectations By $0.90 EPS - MarketBeat
uniQure (NASDAQ:QURE) Shares Down 9.5%Should You Sell? - MarketBeat
uniQure (NASDAQ:QURE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Uniqure NV earnings missed by $0.82, revenue fell short of estimates - Investing.com South Africa
uniQure CEO Matthew Kapusta sells over $360,000 in stock By Investing.com - Investing.com South Africa
uniQure CEO Matthew Kapusta sells over $360,000 in stock - Investing.com India
uniQure CFO Christian Klemt sells shares worth over $186,000 - Investing.com India
uniQure CFO Christian Klemt sells shares worth over $186,000 By Investing.com - Investing.com Australia
Uniqure NV reports results for the quarter ended December 31Earnings Summary - TradingView
uniQure N.V. SEC 10-K Report - TradingView
UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
uniQure Reports 2024 Financial Results and Company Progress - TradingView
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress - GlobeNewswire
uniQure N.V.: A Potential Huntington's Play - Seeking Alpha
(QURE) Technical Data - Stock Traders Daily
Huntington's Disease Market Growth to Accelerate in Forecast - openPR
Pfizer nixes Roche-partnered hemophilia drug (PFE:NYSE) - Seeking Alpha
uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons - Seeking Alpha
uniQure (QURE) Expected to Announce Earnings on Wednesday - MarketBeat
uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66% - Yahoo Finance
24,749 Shares in uniQure (NASDAQ:QURE) Acquired by Palumbo Wealth Management LLC - MarketBeat
uniQure (NASDAQ:QURE) Stock Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
(QURE) Proactive Strategies - Stock Traders Daily
uniQure (NASDAQ:QURE) Stock Price Down 6.7%Should You Sell? - MarketBeat
uniQure (NASDAQ:QURE) Raised to Sell at StockNews.com - MarketBeat
abrdn plc Sells 419,726 Shares of uniQure (NASDAQ:QURE) - MarketBeat
Swelling losses haven't held back gains for uniQure (NASDAQ:QURE) shareholders since they're up 147% over 1 year - Simply Wall St
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four YearsuniQure (NASDAQ:QURE), CSL (OTC:CSLLY) - Benzinga
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B - Quantisnow
uniQure (NASDAQ:QURE) Stock Rating Upgraded by StockNews.com - Defense World
Analysts Set uniQure (NASDAQ:QURE) Price Target at $40.00 - MarketBeat
uniQure Announces Completion of Enrollment in the First - GlobeNewswire
UniQure Advances AMT-191 Trial in Fabry Disease -February 03, 2025 at 12:09 pm EST - Marketscreener.com
uniQure advances gene therapy trial for Fabry disease By Investing.com - Investing.com Australia
uniQure advances gene therapy trial for Fabry disease - Investing.com
Rare Disease Breakthrough: Gene Therapy Trial Shows Promise in Fabry Disease Treatment - StockTitan
uniQure (NASDAQ:QURE) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
HC Wainwright Issues Negative Estimate for uniQure Earnings - MarketBeat
Analysts Set Expectations for uniQure FY2029 Earnings - MarketBeat
uniQure (NASDAQ:QURE) Trading Down 4.8%Should You Sell? - MarketBeat
uniQure Announces Favorable Recommendation from Independent - GlobeNewswire
UniQure Gets Favorable Recommendation From Data Monitoring Committee AMT-162 Trial to Treat Amyotrophic Lateral Sclerosis - Marketscreener.com
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):